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 Septic shock, a severe inflammatory state secondary to a bacterial infection with 
refractory hypotension and tissue hypoperfusion despite adequate fluid resuscitation, is a 
leading cause of mortality in intensive care units worldwide. The mortality rate of septic shock 
patients can exceed 40% in the U.S., highlighting the need for more effective therapies. 
Anakinra, an inflammatory cytokine inhibitor, has been identified as a potential therapy for 
reducing various inflammatory states such as sepsis. Our aim is to evaluate the efficacy of 
anakinra in reducing mortality in patients with septic shock. This double-blind, randomized 
control trial will compare the 28-day mortality of patients who receive a 72-hour intravenous 
infusion of anakinra to a group of patients treated by standard of care alone for septic shock in 
an intensive care setting. Our goal is to evaluate if the addition of anakinra to standard sepsis 
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CHAPTER 1 – INTRODUCTION 
1.1 Background 
Sepsis persists as a major cause of mortality in intensive care units worldwide. 
According to a multicenter randomized trial study published by E. Stevenson et al. in 2014, the 
nationwide 28-day mortality rate of hospitalized adult patients with severe sepsis in the U.S. 
was 29.2%.1 The study also identified up to 27 million hospitalizations associated with sepsis in 
2009 alone. A 2016 international consensus report on sepsis identified patients with sepsis at 
critically ill stages marked by hyperlactatemia and hypotension to have mortality rates as high 
as 54%.2 Worldwide, there are an estimated 31.4 million cases of sepsis per year, contributing 
up to 5.3 million deaths worldwide per year.3 This translates into healthcare costs of billions of 
dollars per year in the U.S. alone.4 In 2013, over $23 billion was spent on sepsis care in the 
U.S., making it the single most expensive condition treated in U.S. hospitals.5 Readmission 
rates following hospitalization for sepsis is also high.6 As compared to common and serious 
medical conditions such as acute myocardial infarction, heart failure, COPD and pneumonia, 
sepsis is the leading cause of unplanned 30-day readmission and is associated with a longer 
mean length of stay than any of the aforementioned conditions.   
The high mortality rate and prevalence of sepsis demands a clear and effective approach 
to treatment that directly translates into improved patient outcome. Understanding the 
inflammatory response involved with any of the stages of sepsis has been a challenge for 
healthcare providers as a whole. Numerous research efforts have attempted to shed light into 
the complex host response that accompanies sepsis. Physicians have continuously attempted to 
design an effective, systemic approach in treating sepsis. Despite these many efforts, sepsis 




Previous approaches to the critical care of septic patients have focused on early 
initiation of antibiotic therapy to control the underlying infection.8 Studies have found that even 
a delay of 6 hours in the initiation of antibiotics can result in increased hospital mortality.8 With 
advances in understanding the pathophysiology of sepsis, however, new therapeutic approaches 
in targeting the mechanism of the underlying rogue inflammatory response itself have been 
introduced, namely the development of novel immunomodulatory agents.  
It is in the light of this approach that the role of interleukin-1 has been identified as a 
potential target for therapy. In sepsis, the host produces pro-inflammatory cytokines, one of 
which is interleukin-1(IL-1).9 Upon activation, IL-1 induces fever, inflammation and 
hemodynamic shock.10 While the activation of a cytokine such as IL-1 can be beneficial in the 
host defense cascade against an invading organism, an exaggerated inflammatory response can 
be equally detrimental to a patient. For example, macrophage activation syndrome(MAS) is a 
state where inflammatory cytokines such as IL-1 are overexpressed, leading to a “cytokine 
storm” (Figure 1). The main clinical features of MAS include pancytopenia, liver dysfunction, 
coagulopathy similar to disseminated intravascular coagulation(DIC), and hyperferritinemia.11 
Clinically and pathologically, MAS bears strong similarity to hemophagocytic 
lymphohistiocytosis (HLH). In fact, MAS, secondary hemophagocytic lymphohistiocytosis, 
and sepsis all share the same mechanism of dysregulated inflammation and may exist along a 
common spectrum.12  
The acute phase of overwhelming inflammation in MAS can subsequently cause 
multiorgan dysfunction syndrome(MODS) – a fatal, sepsis-induced state featuring 
pancytopenia, tissue hemophagocytosis, liver dysfunction, coagulopathy, and/or CNS 




Figure 1. Proinflammatory cytokines, macrophage activation syndrome(MAS) and the cytokine 
storm.11  
The pathogenesis of this cytokine storm, marked by increased levels of numerous 
proinflammatory cytokines including IL-1 and ultimate organ dysfunction is also the hallmark 
of sepsis shock, a state of unregulated host response to an infection.13 While understanding the 
intricate balance of cytokines in the cytokine storm of MAS is challenging, the recognition of 
IL-1 as a major player in the inflammatory cascade supports using the blockade of IL-1 
receptors as a therapeutic approach in septic patients.9  
Interestingly, in sepsis the host also produces its own anti-inflammatory cytokines, such 
as the interleukin-1 receptor antagonist (IL-1Ra) (Figure 2). IL-1Ra’s role is to inhibit the 
formation of an IL-1 signaling complex and provide negative regulation to a host’s response to 
sepsis.14,15  The balance between the pro-inflammatory cytokine IL-1 and anti-inflammatory 
cytokine IL-1Ra is important in the regulated response to an infection. Conversely, an 
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imbalance of IL-1 and IL-1Ra has been implicated as the cause or a severity factor in a number 
of diseases. Therefore, targeting IL-1 in the therapy of inflammatory diseases has been a 
medical challenge marked by many failures and successes.15  
 
 
Figure 2. IL-1 receptor complex and signaling. Binding of the IL-1 receptor antagonist to the 
IL-1R1(receptor) inhibits IL-1 binding and signal transduction.15 
 
 
As efforts continue to understand the complicated pathophysiological role of IL-1 in an 
inflammatory response, studies have linked gene expression of IL-1 receptors/IL-1 receptor 
antagonists to outcome in septic shock.16-18 One example is a meta-analysis by Fang, F. et al 
that studied the association between an interleukin-1 receptor antagonist (IL1RN) gene 86-bp 
VNTR polymorphism and sepsis.18 In this meta-analysis, researchers discovered that although 
IL1RN 86-bp VNTR polymorphism is not associated with sepsis mortality, it is associated with 
increased risk of sepsis. While the definitive mechanism of the association is not clearly 
understood, it can be reasoned that an elevated production of anti-inflammatory cytokines can 
also inadvertently interfere with the host’s natural anti-inflammatory process. Another study by 
Zhang, A. et al. quantitatively weighed the association between the polymorphisms of IL-1 
genes and sepsis. According to this study, polymorphisms of IL-1A-889, IL-1B + 3954 and IL-
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1RN VNTR showed significant associations with the risk of sepsis.17 Furthermore, a 
prospective cohort study by Zapata-Tarres, M. et al. showed an increased prevalence of septic 
shock in childhood acute lymphoblastic leukemia patients with IL-1 receptor antagonist 
polymorphism (ILrN*1/ILrN*2), again showing the impact of IL-1 related genotype variance 
on the outcome of sepsis.19 
 
1.2 Statement of the Problem 
 
Anakinra is a recombinant IL-1 receptor antagonist that is proven to be effective in 
reducing various inflammatory states.9,15,20,21 It works by preventing the binding of IL-1a or IL-
1b to its receptors, effectively blocking the inflammation cascade from propelling further.9 
Historically, anakinra has been studied for ameliorating various inflammatory processes such as 
RA, gout, Type II diabetes, chronic pericarditis, STEMIs and autoinflammatory syndromes 
such as Still’s disease.9,21-23  
 
Figure 3. Timeline of Anakinra Use in Various Inflammatory Processes9 
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While anakinra has been shown to be effective in various inflammatory diseases, its 
therapeutic role remains unknown. Using the same mechanism as in other inflammatory 
diseases, blocking the IL-1 receptor and inhibiting the signal transduction may be useful in 
sepsis. In fact, as early as in the late 1980s, studies suggested correlation between elevated IL-1 
levels and increased mortality from sepsis. The most notable early human trial using anakinra 
as a IL-1 blockade in sepsis was a phase III randomized control trial published in 1997 by Opal 
et al.24 In this double-blinded, randomized control trial, the efficacy of anakinra in patients with 
severe sepsis was analyzed in comparison with a placebo. According to this study, the 28-day, 
all-cause mortality rate was 33.1% in the group of subjects treated with anakinra in addition to 
standard therapy, while the mortality rate in the placebo group was 36.4%. Despite the attempt 
at a pioneering approach, the researchers concluded a 3.3% difference to be insufficient to 
demonstrate a statistically significant reduction in mortality when compared with standard 
therapy.24,25 
It wasn’t until almost two decades after Opal’s original study that anakinra was 
reconsidered as possible treatment for sepsis. In February of 2016, Shakoory et al. published a 
reanalysis of Opal’s phase III trial in the journal Critical Care Medicine.26 The objective of the 
reanalysis was to reevaluate the efficacy of anakinra in decreasing the 28-day mortality in 
septic patients, reanalyzing only those patients with features of macrophage activation 
syndrome as a surrogate for a more severe inflammatory septic response. The investigators 
discovered that while anakinra did not prove efficacious in Opal’s original trial, regrouping the 
study subjects according to presence or absence of features associated with macrophage 
activation syndrome did appear to improve sepsis survival outcomes.26  
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The reanalysis indicates that patients with septic shock may benefit from interleukin-1 
receptor blockade with anakinra given the overlapping clinical features of MAS and septic 
shock. 
 
1.3 Goals and Objectives  
 
In the light of this intriguing finding, a randomized, controlled trial focusing on septic 
shock patients may provide insight into the efficacy of anakinra as a therapeutic agent in 
critically ill septic patients at high risk of death. Our study is designed to focus specifically on 
patients with septic shock – a subgroup of septic patients with not only end organ dysfunction 
but also with a dysregulated inflammatory response similar to MAS. We are hopeful that while 
earlier studies have not found significant improvement in mortality using anakinra in septic 
patients, our more targeted approach to the most critically ill, septic shock patients will provide 
a better outcome in reduction of mortality. If effective, this therapy will provide a novel 
treatment option for patients with septic shock.  
 
1.4 Hypothesis  
 
We hypothesize that adult patients in septic shock treated with anakinra in addition to 
standard of care therapy will have a decreased 28-day mortality rate as compared to patients 





1.5 Definitions  
 
Sepsis and Septic Shock 
 
For decades, defining sepsis has been challenging. In 2001, several international critical 
care societies convened to define sepsis as a systemic inflammatory process that can be divided 
into three stages: sepsis, severe sepsis and septic shock.27 The Sepsis Definitions Conference 
defined the three stages as follows: “Sepsis is defined as the presence of infection plus some of 
the listed signs and symptoms of sepsis. Severe sepsis is defined as sepsis complicated by organ 
dysfunction, and septic shock as severe sepsis with acute circulatory failure characterized by 
persistent arterial hypotension unexplained by other causes.”28 Despite this definition, defining 
who would have poor outcomes in sepsis remained difficult until the recent publication in 2016 
of the Sepsis-3 guidelines.2 According to the new guidelines, the term “severe sepsis” has been 
dropped and the systemic inflammatory state to an infection is categorized into sepsis and 
septic shock. Sepsis is now defined as “life-threatening organ dysfunction caused by a 
dysregulated host response to infection” and septic shock as “a subset of sepsis in which 
underlying circulatory and cellular/metabolic abnormalities are profound enough to 
substantially increase mortality.”2  
 
SIRS, SOFA and qSOFA – Clinical Criteria for Sepsis 
 
There are two widely used methods in clinically identifying sepsis in patients: the SIRS 
(Systemic Inflammatory Response Syndrome) Criteria and the SOFA (Sequential Organ 
Failure Assessment) Criteria (Tables 1 and 2). Traditionally, sepsis is defined as 2 or more of 
the SIRS Criteria with a source of infection. However, the new Sepsis-3 Guidelines recommend 
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the use of SOFA scoring to define the organ dysfunction of a potentially septic patient due to 
higher predictive in-hospital mortality compared to the SIRS criteria. Using SOFA, organ 
dysfunction is recognized as an increase in the SOFA score of 2 points or more.2  
 Quick-SOFA (qSOFA) is a new bedside clinical scoring system of three components: 1) 
respiratory rate of 22/min or greater, 2) altered mentation, or 3) systolic blood pressure of 100 
mmHg or less.2 The utility of qSOFA lies in its simplicity and the ability to quickly assess 
potentially septic patients. However, due to its limitations in both sensitivity and specificity, we 
will not be utilizing this scoring system in our study.  
 
Clinical Criteria for Septic Shock 
 
Sepsis-3 guidelines define septic shock as sepsis plus the need for vasopressor therapy 
to elevate mean arterial pressure (MAP) to ≥ 65 mmHg and lactate to >2 mmol/L (18 mg/dL) 
despite adequate fluid resuscitation (Table 1).2  
 




Table 2. Sequential [Sepsis-Related] Organ Failure Assessment Score2 
 
Standard of Care (for Septic Shock) 
 
Current standard of care for septic shock in intensive care and emergency care settings 
include 1) rapidly treating the underlying infection with broad-spectrum antibiotic therapy 
followed by subsequent narrowing of antibiotics to appropriate antimicrobial agents, 2) 
hemodynamic support through improving stroke volume and intravascular volume 
resuscitation, and 3) the use of vasopressors to counteract vasoplegic shock. However, septic 
shock management remains largely variable and is dependent on the severity of the disease and 
individual response of the patient. For example, recent studies have shown a more “flexible” or 
“conservative” approach to fluid resuscitation rather than an aggressive, universal approach 
may be more beneficial to patients in septic shock.7 Practice variation still exists and it is 






For the purposes of our study, we define mortality rate as the percentage of subjects that 
achieve the outcome of death from all causes within 28 days of study enrollment. The 
percentage will be calculated by the number of deceased subjects divided by the number of 







1. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of 
mortality trends among patients with severe sepsis: a comparative meta-analysis*. 
Critical care medicine. 2014;42(3):625-631. 
2. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus 
Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):801-810. 
3. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and 
Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir 
Crit Care Med. 2016;193(3):259-272. 
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and 
associated costs of care. Critical care medicine. 2001;29(7):1303-1310. 
5. Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive 
Conditions by Payer, 2013: Statistical Brief #204. Healthcare Cost and Utilization 
Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research 
and Quality (US); 2006. 
6. Mayr FB, Talisa VB, Balakumar V, Chang CH, Fine M, Yende S. Proportion and Cost 
of Unplanned 30-Day Readmissions After Sepsis Compared With Other Medical 
Conditions. Jama. 2017;317(5):530-531. 
7. Taeb AM, Hooper MH, Marik PE. Sepsis: Current Definition, Pathophysiology, 
Diagnosis, and Management. Nutr Clin Pract. 2017;32(3):296-308. 
8. Dickinson JD, Kollef MH. Early and Adequate Antibiotic Therapy in the Treatment of 
Severe Sepsis and Septic Shock. Current Infectious Disease Reports. 2011;13(5):399-
405. 
9. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in 
humans. Seminars in immunology. 2013;25(6):469-484. 
10. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor 
and treatment of the septic shock syndrome. The Journal of infectious diseases. 
1991;163(6):1177-1184. 
11. Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential 
for cytokine- directed therapies. Annual review of medicine. 2015;66:145-159. 
12. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and 
guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus 
Conference Committee. American College of Chest Physicians/Society of Critical Care 
Medicine. Chest. 1992;101(6):1644-1655. 
13. Sen ES, Clarke SL, Ramanan AV. Macrophage Activation Syndrome. Indian journal of 
pediatrics. 2016;83(3):248-253. 
14. Freeman BD, Buchman TG. Interleukin-1 receptor antagonist as therapy for 
inflammatory disorders. Expert Opin Biol Ther. 2001;1(2):301-308. 




16. Meyer NJ, Ferguson JF, Feng R, et al. A functional synonymous coding variant in the 
IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med. 
2014;190(6):656-664. 
17. Zhang AQ, Pan W, Gao JW, et al. Associations between interleukin-1 gene 
polymorphisms and sepsis risk: a meta-analysis. BMC Med Genet. 2014;15:8. 
18. Fang F, Pan J, Li Y, et al. Association between interleukin 1 receptor antagonist gene 
86-bp VNTR polymorphism and sepsis: a meta-analysis. Hum Immunol. 2015;76(1):1-
5. 
19. Zapata-Tarres M, Arredondo-Garcia JL, Rivera-Luna R, et al. Interleukin-1 receptor 
antagonist gene polymorphism increases susceptibility to septic shock in children with 
acute lymphoblastic leukemia. Pediatr Infect Dis J. 2013;32(2):136-139. 
20. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying 
therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an 
international multicenter series. Arthritis and rheumatism. 2011;63(2):545-555. 
21. Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory 
diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 
and an emerging role for cytokines beyond IL-1. Clin Exp Immunol. 2012;167(3):391-
404. 
22. Jain S, Thongprayoon C, Espinosa RE, et al. Effectiveness and Safety of Anakinra for 
Management of Refractory Pericarditis. Am J Cardiol. 2015;116(8):1277-1279. 
23. Kumar A, Kato H. Macrophage Activation Syndrome Associated with Adult-Onset 
Still's Disease Successfully Treated with Anakinra. Case Rep Rheumatol. 
2016;2016:3717392. 
24. Opal SM, Fisher CJ, Jr., Dhainaut JF, et al. Confirmatory interleukin-1 receptor 
antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-
controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator 
Group. Critical care medicine. 1997;25(7):1115-1124. 
25. Siegler BH, Brenner T, Uhle F, Weiterer S, Weigand MA, Hofer S. Why a second look 
might be worth it: immuno-modulatory therapies in the critically ill patient. Journal of 
thoracic disease. 2016;8(6):E424-430. 
26. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is 
Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage 
Activation Syndrome: Reanalysis of a Prior Phase III Trial. Critical care medicine. 
2016;44(2):275-281. 
27. Levy MM. The challenge of sepsis. Critical Care. 2004;8(6):1-2. 
28. Vincent J-L, Korkut HA. Defining Sepsis. Clinics in Chest Medicine. 2008;29(4):585-
590. 
29. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 
2016;353:i1585. 
30. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International 
Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 
2017;43(3):304-377. 
31. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international 





CHAPTER 2 – REVIEW OF THE LITERATURE   
2.1 Introduction 
 
An electronic literature review was conducted using the MeSH database system of 
PubMed, Ovid, and Cochrane Review. We used a comprehensive list of combinations of the 
key terms: “sepsis”, “septic shock”, “interleukin-1”, “IL-1”, “anakinra”, “mortality”, and “28-
day mortality”. We included both retrospective and prospective studies as well as meta-
analyses, dating back to 1991. Editorials or non-systematic reviews were excluded from our 
references. The reason for such expanded retrospective research of literature in time was due to 
lack of studies conducted in the use of anakinra for sepsis and to evaluate the evolution of 
sepsis treatment.  
 
2.2 Review of empirical studies  
 
Our empirical literature review focused on three things:  
1) studies that identified the mortality of sepsis, to highlight the weight of the problem we 
wanted to address;  
2) research in understanding the mechanism behind sepsis, septic shock and the potential anti-
inflammatory therapies; and 
3) studies using anakinra as therapy.  






Sepsis and Mortality 
 
As mentioned previously, observed mortality rates from sepsis can exceed 40%. We 
looked at three main articles that discussed sepsis-associated mortality rates and the factors that 
affected the outcome, if relevant.  
The earliest study we reviewed was a meta-analysis of retrospective and prospective 
studies published by Friedman et al. in 1998, looking at mortality rates in septic shock patients 
between 1958-1997.1 The review focused on changes in mortality in septic shock over time. To 
achieve this goal, Friedman and his colleagues reviewed literature from 1958-1997 on the 
MEDLINE database and identified 131 studies (99 prospective and 32 retrospective) involving 
a total of 10,694 patients. The study reported the overall mortality rate of patients in septic 
shock across the 131 studies to be an astonishing 49.7%. The study also noted a decreasing 
trend of mortality over the study period, at r = 0.49 with p < 0.05. The study also looked at 
variability in mortality according to site of infection and changes in the most common 
organisms over time.1  
While the study raises significant alarm in the high mortality rate identified, it was 
confounded by the lack of consistency among the studies in defining severe sepsis and septic 
shock and the varying entry criteria for each study. Also, the researchers did not standardize the 
studied population by using a severity score for sepsis, thus were unable to stratify or control 
for the severity of the illness which limited their analysis. The analysis included studies with 
different designs and different aims, further limiting the internal validity of the study. Finally, 
the researchers also did not specify the countries from which the studies were conducted. 
In 2014, a more thorough meta-analysis was published by Stevenson, E et al., reviewing 
36 sepsis trials from 1993-2009.2 The study was conducted in response to an observation that 
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there appeared to be a declining sepsis mortality, leading researchers to question whether the 
decline was due to advances in practices or merely a mirage reflecting changes in classification 
of patients with “severe sepsis”. The new classification could have possibly led to the inclusion 
of less critically ill patients in its definition and therefore falsely reflecting better outcomes. In 
this meta-analysis, researchers reviewed 36 multi-centered, randomized prospective trials that 
included a total of 14,418 adult (>18 years old) participants with severe sepsis or septic shock 
in hospitals across the U.S and abroad. Single-center trials were excluded to reduce bias from 
center-specific outcomes. The primary outcome explored in this study was 28-day all-cause 
mortality, as planned in our study. The nearly two-decade span of data showed a mortality rate 
of 29-46.9%, with a decreasing trend over time consisting of a 3.0% drop annually (95% CI, 
0.8%–5.0%; p = 0.009). The average 28-day mortality rate across all trials was 33.2%. The 
researchers also calculated standardized mortality ratios for each trial using observed and 
predicted mortality rates to identify whether discrepancies existed from differing sepsis 
identification criteria. The study showed decline in mortality ratio over time, confirming the 
decrease in mortality rates. They also observed a similar trend among trials using different 
sepsis identification criteria, suggesting the downtrend in mortality rate was not a result of the 
simple re-classification of patients.  
While the analysis was useful in reviewing mortality rates and trends leading up to 
2009, the study had its limitations in reflecting true mortality rates in severe sepsis/septic 
shock. Due to the nature of a meta-analysis, data regarding potential confounders at individual 
patient-by-patient level were unavailable and thus unadjusted for. Also, although the multi-
national, multi-centered trials allowed for larger sample sizes, the results are vulnerable to 
internal validity due to variability in practices between different nations. Furthermore, the large 
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number of participants may falsely represent statistically significant results while being 
exposed to a greater number of confounding biases that are not controlled for. Nonetheless, 
Stevenson et al.’s study draws attention to the high mortality rate associated with sepsis 
worldwide and despite the downtrend at the turn of the century, it shows that mortality rates in 
critically-ill septic patients remains high.  
Most recently, in 2016, Fleischmann, C. and his colleagues made another attempt at 
evaluating global mortality rates in septic patients.3 In this systematic review, researchers 
investigated the incidence and the mortality rate of sepsis and severe sepsis between 1979-
2015, using 15 international citation databases in an attempt to assess the global burden of 
sepsis. They searched any relevant literature on sepsis that reported evidence-based 
epidemiologic data within a given time frame but excluded studies that were limited to 
subgroups of sepsis or certain patient populations such as cancer patients or pediatric patients. 
Ultimately the study included 27 international sepsis trials from 18 different countries. 
According to their study, the global population incidence for in-hospital sepsis cases was 
estimated to be 288 per 100,000 person-years. Individually, the studies reviewed showed sepsis 
incidence ranging from 73.6 per 100,000 inhabitants in the United States (1979) to 1,180 per 
100,000 inhabitants in Australia (2007–2008). When limiting the data to more recent years 
(2003–2015) the study revealed an even higher incidence at 437 per 100,000 person-years. For 
in-hospital severe sepsis cases, including septic shock, the investigators reported an incidence 
of 148 per 100,000 person-years. During the last decade, the incidence rate for severe sepsis 
was 270 per 100,000 person-years. The investigators used 95% confidence intervals for their 
analysis with t=0.55-0.99.  
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28-day in-hospital mortality rates from sepsis showed great variability between studies, 
ranging from 5% to 42.5%, to an estimate of 21% worldwide. For severe sepsis, the estimated 
worldwide mortality rate was higher at 28%. Only looking at 2003-2015, the analysis showed a 
slightly decreased 28-day mortality rate of 17% in sepsis and 29% in severe sepsis.  
The investigators in this study recalculated the population-level incidence rates from 
each study using the number of hospital sepsis cases provided in each study and census data 
reported for the time of that study. This reduced the variability in reported rates from different 
calculation methods in the original studies. However, the wide range of t values (0.55-0.99) 
shows the great difference in rates between studies as original publications were of different 
populations in different countries. While it may be impossible to control for the variables 
between studies from different countries, patient populations and practices, we also note that 
the great range in incidence and mortality rates may also reflect the heterogeneity of 
identification of sepsis cases among administrations. Achieving a consensus on defining sepsis 
has been an ongoing challenge and the difference in definition criteria for sepsis and severe 
sepsis among coding systems make global epidemiologic assessment challenging.  
The most prominent limitation of this study lies in the fact that only 18 higher-income 
countries were included in the study due to lack of sufficient sepsis data from lower-income 
countries, limiting its predictive value as a true assessment of sepsis cases worldwide. We can 
assume sepsis incidence and mortality rates may be higher in lower-income countries, if we 
assume these countries also suffer from higher prevalence of infectious diseases and less 
efficient infection control.  
While the studies by Friedman, Stevenson, and Fleischmann each showed its own 
strengths and weaknesses, they all showed an alarmingly high mortality among the populations 
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studied. Despite the declining hospital mortality rates shown in the study by Stevenson, E. et 
al., the study by Fleischmann demonstrated the continuing burden of sepsis worldwide, 
encouraging the need for continued research in treatment for sepsis.2,3 
 
Table 3. Sepsis Mortality in Literature 
 
Inflammatory Cascade and Anti-inflammatory Agents in Sepsis Treatment 
 
While the previous studies mentioned exposed the high disease burden of sepsis, the 
next group of studies supports our understanding of the physiologic mechanism that lies behind 
the high mortality of sepsis as well as the use of anti-inflammatory agents as treatment.   
In 1991, Charles A. Dinarello published an article discussing the role of 
proinflammatory cytokines in treatment of septic shock.4 The article focused mainly on two 
cytokines, interleukin-1(IL-1) and tumor necrosis factor(TNF). In his article, Dinarello argued 
that treating septic shock by either blocking the endotoxins secreted by the causative organisms 
or by neutralizing the antibodies was not an effective method. He suggested the direct 
inhibition of IL-1 or TNF would be a possible treatment strategy for sepsis by blocking the 
inflammation process and therefore a potential solution to reducing the high mortality 
associated with septic shock. He supported his argument by proving that an endogenous IL-1 
Date of Study Author Type of Study Study Population Primary Outcome Study Results
1998 Friedmann, G Meta-analysis 131 studies (99 prospective, 32 
retrospective) involving a total of 
10,694 patients
overall mortality Overall mortality rate 49.7%
2014 Stevenson, E Meta-analysis 36 sepsis trials globally from 1993-
2009, total of 14,418 participants 
with severe sepsis and septic shock
28-day mortality Observed mortality rate between 
1993-2009: 29-46.9%, ave. 33.2%
2016 Fleischmann, C Meta-analysis 27 international sepsis trials from 
1979-2015 in 18 countries, total of 
>2.8 million sepsis cases
incidence and in-
hospital mortality
Incidence, mortality rate for:        
sepsis - 437 per 100,000 person-





receptor antagonist blocks shock and death due to Escherichia coli as well as its efficacy in 
treating a variety of inflammatory diseases.  
Three years later, Charles Natanson presented a study at the 1994 NIH Conference 
highlighting the limitations of the new approach to sepsis therapy. In this study, Natanson 
analyzed preclinical and clinical trial data of antiendotoxin antibodies and anti-cytokine 
therapies for sepsis. The 10 clinical trials discussed in this study did not produce conclusive 
results to establish the safety or benefit of using antiendotoxin antibodies or anti-cytokines in 
septic shock.5 Natanson noted that although IL-1 inhibition studies have shown some benefit in 
animal models, it has not shown clear improvement in human trials. He also discussed the 
limitations of searching for a therapy when the exact mechanism of the inflammatory response 
is yet poorly understood. While inhibiting the host inflammatory response may be a premise for 
new therapy, the complexity of the mechanism in which the cytokines function greatly limits 
identifying a successful target for therapy. 
 
Table 4. Literature on IL-1 Blockade 
 
Anakinra as Therapy  
 
Anakinra, a recombinant interleukin-1 receptor antagonist, has been most popularly 
used in treating chronic inflammatory diseases such as rheumatoid arthritis.6,7 As such, there 
have not been many studies conducted which focus on anakinra as a therapy for sepsis. The 
most notable study that introduced anakinra as a potential new treatment was a randomized, 
Date of Study Author Study Results
1991, 1993 Dinarello, C
Review of the role of IL-1 in septic shock and its 
blockade
1994 Natanson, C.




double-blind, confirmatory phase III trial published in July 1997 by Steven Opal.8 In this study, 
Opal and his colleagues designed a placebo-controlled, phase III clinical trial studying the 
association between sepsis mortality and use of anakinra as therapy. This study was modeled 
after an earlier phase III trial by Charles Fischer and Opal9 published four years earlier that 
tested two different doses of anakinra in septic patients versus placebo. The initial study did not 
show a significant reduction in mortality (28day, all-cause mortality was 34% (102/302) in the 
placebo group, 31% (91/298) in the 1.0 mg/kg/hr rhIL-1ra group, and 29% (86/293) in the 2.0 
mg/kg/hr rhIL-1ra treated group (p = .23)), however the researchers retrospectively discovered 
that the most critically ill patients enrolled in their study had slightly favorable survival benefit 
with anakinra.    
In the confirmatory study performed in 1994, the researchers recruited 906 patients with 
sepsis and/or septic shock from across 91 ICUs in North America and Europe. The patients 
were randomized to either receive anakinra 100 mg bolus + 72-hr infusion at 2 mg/kg/hr in 
addition to standard therapy or standard therapy alone (placebo). The primary outcome 
assessed was all-cause 28-day mortality. Although the study was originally designed to recruit 
1,300 patients, the researchers set an interim analysis to be performed when approximately half 
of the target population had been enrolled and had completed the trial. When this interim 
analysis was performed, the study had recruited 906 patients that met the inclusion criteria. 
Complete data was available for assessment of 696 patients. According to the interim analysis, 
the 28-day, all-cause mortality rate was 33.1%(116/350) in the anakinra treatment group, while 
the mortality rate in the placebo group was 36.4% (126/346), yielding a 9% reduction in 
mortality rate (p = .36). With these results, researchers concluded the intervention failed to 
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demonstrate a statistically significant reduction in mortality when compared with standard 
therapy.  
 Although the data failed to show marked reduction in mortality as predicted, the study 
was well designed in that it was performed in a large cohort from multiple medical centers in 
various countries. There were a total of 11 participating countries with no single center 
contributing more than 4% of the entire patient population in the study, strengthening the 
generalizability of the study. Nonetheless, a multi-national, multi-centered clinical trials also 
has its limitations such as the variability between centers in clinical practice, treatment 
protocol, prevalent pathogens and disease recognition and reporting patterns. The study was 
also double-blinded to reduce observer bias. However, the researchers reported they may have 
been susceptible to bias in favor of a good outcome due to the favorable results published in the 
earlier trials. Another confounding factor of the poor results may be due to the improvements in 
sepsis care mortality itself, due to advances in disease management. Continuous improvements 
have been made in managing critically ill patients with septic shock that may diminish the 
room to make improvements in the clinical care of this population.  
In summary, Opal and his colleagues concluded the phase III trial of anakinra use in the 
treatment of septic patients to be unsuccessful in demonstrating a benefit to continue the trial. 
They suggested the need for additional studies to understand the activity of IL-1ra as well as 
more studies that target a well-controlled specific population within septic patients to observe a 
direct therapeutic benefit.  
In the following years, anakinra stayed mainly as a therapy option for inflammatory 
states such as RA, gout, diabetes, chronic pericarditis, and autoinflammatory syndromes as well 
as MAS. Most clinical studies have been focused in these disease states as briefly outlined 
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below. Of note, all studies involving anakinra report little to no adverse side effects of anakinra. 
2-7 In one study, 31% of the anakinra-treated patients developed transient injection site reaction 
that responded to oral diphenhydramine and local hydrocortisone.10 
Among the more recent studies in the last decade, an article was published in Nature 
Reviews Rheumatology in 2008, of a 13-year-old girl with systemic juvenile idiopathic arthritis 
complicated by macrophage activation syndrome was successfully treated with anakinra.11 Also 
in 2011, Nigrovic, PA7 studied the efficacy of anakinra as first-line therapy for systemic 
juvenile idiopathic arthritis(JIA) and found rapid resolution of systemic symptoms and 
prevention of refractory arthritis in nearly 90% of their study subjects. This study helped 
transition the use of anakinra as first-line therapy in systemic JIA from a novel rescue. Later 
that year in August, Miettunen, PM et al12 reported a case series of 12 patients in which they 
reported resolution of severe pediatric rheumatic disease-associated macrophage activation 
syndrome with the added use of anakinra with conventional immunosuppressive therapy. 
Following the successful treatment, they concluded the early use of anakinra, used in 
conjunction with conventional immunosuppressive therapy, is effective in severe MAS. 
Additionally, in 2014, a retrospective review of eight patients with suspected secondary HLH 
(hemophagocytic lymphohistiocytosis), an inflammatory response with similar features to 
sepsis, in the PICU at Helen DeVos Children’s Hospital in Michigan which showed positive 
results in decreasing the systemic inflammation with anakinra use.13 Most recently in 2015, a 
retrospective review by Jain, S10 evaluated 13 cases of treatment-refractory recurrent 
pericarditis treated with anakinra and found that all 13 patients experienced partial to complete 
resolution of symptoms, suggesting anakinra as an effective alternative agent for the 
management of glucocorticoid-dependent recurrent pericarditis. 
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As such, while anakinra has shown to be effective in various inflammatory diseases 
through functional IL-1 receptor blockade as evidenced in the previously mentioned 
experimental trials and case reviews, its uses in sepsis has remained limited. To date, the most 
cited and valued clinical study investigating the value of rhIL-1RA as therapeutic option in 
patients with sepsis remains to be Opal’s study in the early 1990s, although the disappointing 
results failing to show a significant reduction in mortality had discouraged the utility of 
anakinra in sepsis management.  
However, a recent reanalysis published in 2016 by Bita Shakoory14 suggests otherwise. 
In this reanalysis study, the patients from Opal’s confirmatory phase III trial were regrouped 
based on the features of macrophage activation syndrome(MAS) – patients with hepatobiliary 
dysfunction(HBD) and disseminated intravascular coagulation(DIC) were grouped together 
while those without the two clinical signs of MAS comprised the control group. Patients were 
determined to have HBD if they showed presence of ≥2 of the following: prolonged 
prothrombin time (PT), elevated blood levels of aspartate or alanine aminotransferase and/or 
serum bilirubin levels above 2.5 mg/dL. DIC was defined as abnormal platelet counts with 
prolonged PT or partial thromboplastin time (PTT) in participants without anticoagulation or 
other pre-existing factors affecting anticoagulation. Following the regrouping of patients, the 
authors of the reanalysis discovered that while the 28-day survival rate remained statistically 
non-significant in the non-hepatobiliary dysfunction/disseminated intravascular coagulation 
patients (71.4% in anakinra treatment group vs. 70.8% in the control group), the 28-day 
survival rate in the hepatobiliary dysfunction/disseminated intravascular coagulation group was 
65.4% (anakinra) vs. 35.5% (control). The significant improvement in the mortality rate in the 
reanalysis study revisited anakinra as a potential therapeutic agent in patients with septic shock 
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and highlighted the need for a second evaluation of a specific subgroup of these patients for the 
advantages of IL-1Ra treatment.   
Despite the promising results, this study was not without limitations. Since it was a 
reanalysis of a previous trial, the study had no control over assigning equal number of patients 
to each study arms. Although 763 patients from the original study were included in the 
reanalysis, the majority of the cases presented only with DIC or MBD and not both. Only 43 
patients had both DIC and HBD, 26 of which were treated with anakinra, leaving 17 in the 
placebo arm and creating an underpowered study. Nevertheless, the study results suggested a 
targeted population, more specifically patients with septic shock, may benefit from interleukin-




Table 5. Use of Anakinra in Literature 
 
 
Date of Study Author Type of Study Study Population Intervention Primary Outcome Study Results Significance 
1994 Opal, SM Phase III, 
Randomized 
Control Trial
893 patients with 
sepsis





mortality was 34% 
(102/302) in the placebo 
group, 31% (91/298) in 
the 1.0 mg/kg/hr rhIL-
1ra group, and 29% 
(86/293) in the 2.0 
mg/kg/hr rhIL-1ra 
treated group (p = .23)
Did not show 




trend in critically ill 
subgroup
1997 Opal, SM Phase III, 
Randomized 
Control Trial










33.1% (116/350) in the 
rhIL-1ra treatment 
group, while the 
mortality rate in the 
placebo group was 
36.4% (126/346), yielding 
a 9% reduction in 
mortality rate (p = .36). 
Mortality rate 36% in 
placebo group vs. 33% in 
patients receiving IL-1ra
The study was 
terminated after an 
interim analysis found 
that it was unlikely that 
the primary efficacy 
end points would be 
met






anakinra 1mg/kg SQ daily in addition 
to standard prednisolone and 
ciclosporin therapy
N/A Significant improvement 
in symptoms
Showed potential for 
anakinra use in therapy 
for sJIA complicated by 
MAS
2011 Nigrovic Systematic 
Review
46 patients with 
systemic JIA from 
4 countries
anakinra +/- corticosteroids or 
other DMARDs
N/A Partial to full resolution 
of symptoms in >95% of 
patients
Proposed anakinra as 
an effective first-line 
therapy for sJIA





anakinra 2mg/kg/day(max 100mg) in 
addition to pre-existing MAS 
therapy 
N/A All patients achieved 
MAS remission after 
addition of anakinra 
within a median of 13 
(range 2–19) days
Showed effectiveness 
of anakinra in severe 
MAS
2014 Rajasekaran Retrospective 
Case Series
8 pediatric 





anakinra at variable doses +/- IVIG 
or corticosteroids
N/A Decline in inflammatory 
markers after anakinra 
use
Showed therapeutic 
potential for HLH, 
which  has similar 
clinical features as 
sepsis
2015 Jain Systematic 
Review





anakinra at various doses after 
refractory to NSAIDs, colchicine and 
prednisone for >6mo.
N/A all 13 patients 
experienced partial to 
complete resolution of 
symptoms
Proposed anakinra as 
an effective alternative 
agent for treatment 
refractory pericarditis
2016 Shakoory Re-analysis of 
phase III trial 
by Opal













28-day survival rate in 
the HBD + DIC group was 
65.4%(anakinra) vs. 
35.5%(control)
Revisited anakinra as a 
potential therapeutic 




2.3 Confounding Variables in Literature 
 
In Opal’s original study the 28-day all-cause mortality rate did not differ significantly 
between treatment groups by the site/source of infection, type of pathogen, presence of organ 
dysfunction at the time of study entry or the predicted mortality at the time of study entry, 
eliminating many of our confounding variables.8 However, given that the study was conducted 




Sepsis starts with an infection in the host and the variability of the infectious source or 
pathogen itself, may be a confounding factor in a study. One of the major concerns is the effect 
of infection source control (i.e. eradicating or hindering the infectious organism) on the 
outcome of sepsis. Current guidelines recommend intervention for source control within hours 
after diagnosis.  
Most recently, in 2017, a Spanish multi-center, prospective observational study of 99 
ICUs published by Martinez, M. et al15 attempted to determine the impact source control and its 
timing in the management of sepsis. The study enrolled 3,663 patients with severe sepsis or 
septic shock during three 4-month periods between 2011 and 2013. A total of 1,173 patients 
(32%) underwent source control and compared with patients who did not require source 
control, patients who underwent source control had greater prevalence of shock, major organ 
dysfunction, bacteremia, inflammatory markers, and lactic acidemia. Also, resuscitation 
compliance was worse. However, both hospital mortality and crude ICU mortality was lower in 
the source control group, leaving mixed conclusions on whether timely source control directly 
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affects sepsis mortality. One of the reasons of these mixed results can be attributed to the 
heterogeneity of the process of source control. Rather than a simple antibiotic therapy, proper 
source control is a multidisciplinary team effort that is linked to the management of a septic 
patient.16 
Another previous study reported comprehensive data on infection in sepsis. Gotts, et 
al17 published in 2016 an extensive review of 14,000 adult patients in 1265 ICUs from 75 
countries on a single day in May 2007. The researchers included demographic, physiological, 
bacteriological, therapeutic and outcome data in their analysis to better understand sepsis. Of 
7,000 patients identified with an infection, the most common site of infection was the lungs 
(64%). The most common isolated organism were Gram negative organisms such Pseudomonas 
spp. (20%) and Escherichia coli (16%).  While the study does not specify the direct correlation 
between variables of infection and mortality, it can be supposed that the variables surrounding 




Both Opal’s study and Shakoory’s reanalysis stratified their data by gender and age and 
both studies noted that there was no significant difference in mortality by these categories. 
However, a review article published recently by Gotts, J. et al17 invites some skepticism. Gotts 
and his colleagues report that while women have lower incidence of sepsis than men, the effect 
of gender on mortality rate was unclear. The researchers suggested the difference may be 
attributed to sex hormones and its effects on immunity as well as possible differences in 
cardiovascular physiology and response to infection.17,18 The study by Gotts also noted that 
patients are more susceptible to sepsis with increased age.17 The increased risk of sepsis can be 
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attributed to the elderly population having more comorbid conditions or generally less 
physiological capacity to fight off an infection. However, a multivariate analysis adjusting for 
comorbid conditions still showed that patients aged 65 or more with sepsis were 2.3 times more 




Since the etiology of sepsis involves an initial infection, any causes of 
immunosuppression are risk factors for sepsis17,19,20. A multi-centered, prospective 
observational study conducted between 1997-2011 in French ICUs that in patients with severe 
sepsis or septic shock concomitant with immunodeficiency had increased risk of mortatlity.21 In 
the analysis of 1,981 patients, the 28-day mortality was 31.3% in the immunocompromised 
group compared to 28.8% in the immunocompetent group(P=0.26). The conditions identified in 
the study to have association with increased mortality were AIDS, non-neutropenic solid tumor, 
nonneutropenic hematologic malignancies and all-cause neutropenia.21  
 
The Obesity Paradox  
 
While obesity is considered a risk factor of many chronic diseases, the association 
between obesity and mortality in sepsis has been mixed. While some studies show no 
association between obesity and mortality, other studies have shown either a positive or 
negative correlation with increased mortality.22 In a systematic review of the association 
between obesity and in-hospital mortality among septic patients, Trivedi, V et al identified 
three studies that reported no significant association between obesity and mortality as well as 
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one study that showed increased mortality. The analysis also identified three studies where 
mortality among obese patients were lower than other counterparts.22 While there are many 
factors that may contribute to variability in sepsis care in obese patients such as underlying 
comorbidities, fluid resuscitation, ventilation requirements or antibiotic administration, the 
paradoxical findings of decreased mortality in obese patients with sepsis may be associated 




Studies have shown increased risk of mortality in septic patients that are subject to 
inter- or intra-facility transfers, most presumably attributed to the delay of early sepsis care.23,24  
In a 1998 single-centered retrospective cohort study of 41 patients with septic shock, Lundberg, 
J and his colleagues compared the mortality between general ward and ICU setting care. The 
study found increased odds ratio of death for ward patients compared to ICU patients (3.57) 
and a delay of fluid administration and inotropic support in patients that developed septic shock 
in a ward setting.23 The delay in sepsis management for inter-facility transferred patients was 
confirmed in a more recent study published in 2015 by Faine, B et al.24 Also a single-center 
retrospective cohort study, this study reviewed 193 patients with severe sepsis and septic shock 
treated between 2009-2014. The patients were identified by whether they had been transferred 
from another local hospital or if they presented to the admitting facility directly through the 
emergency department. The results of the study showed that with similar illness severity, inter-
hospital transferred patients were less likely to have received fluid resuscitation by 3 hours of 
care (54% vs 89%, p<0.001). However, the study did not find significant differences in the 
length of stay in the ICU or mortality.24  
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2.4 Review of relevant methodology  
 
Study Design  
 
Our goal was to design a study largely based on the based on the phase III trial of 
anakinra in sepsis by Opal et al.8,14 However, as suggested in Shakoory’s reanalysis, we 
decided to target patients in a more critical stage of sepsis – septic shock, to evaluate the 
efficacy of anakinra in this targeted population. Opal and his colleagues designed a 
multicentered, double-blind, randomized control trial of reviewing all-cause 28-day mortality in 
sepsis upon which we modeled our study.8 While a multicentered trial would provide better 
generalizability as well as better chance of recruiting a large sample size, we decided to design 
a single-center trial to eliminate center-specific variability in practices. Also, we deemed that 
based on the estimated incidence of septic shock at YNHH, we were confident we would be 
able to reach our sample size goal of 394 patients within the two-year timeframe of this study. 
To achieve the goal of assessing the efficacy of an intervention (anakinra) in a clinical trial, we 
determined a prospective experimental design would be necessary as in Opal’s study. Thus, we 
propose a randomized, placebo-controlled clinical trial that allows for evaluation of the cause 
and effect of our intervention.  
 
Inclusion and Exclusion Criteria (Sepsis-3 definition, SOFA, qSOFA) 
 
The inclusion and exclusion criteria for our proposed study is similar to the criteria used 
in Opal’s confirmatory phase III trial8 (See Appendices I & III). However, we revised the 
inclusion criteria to include the most recent definition for sepsis and septic shock to better 
match our target population. The entry criteria for our study utilizes the SOFA scoring system 
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as well as the current revised definition of septic shock according to the Sepsis-3 consensus 
discussed in Chapter 1.25  
In our proposed study, we will be following the new Sepsis-3 Guidelines 
recommendation to use the SOFA scoring system to define the organ dysfunction of a 
potentially septic patient. Based on these guidelines, the authors recommended use of SOFA 
scoring to define sepsis, where organ dysfunction is recognized as an increase in the SOFA 
score of 2 points or more, which we will use in our study. While we will not be using qSOFA 
scores in our screening of patients, the following figure (Figure 3) depicts a proposed clinical 
decision-making algorithm for evaluating patients for sepsis or septic shock. 
 
 
Figure 4. Operationalization of Clinical Criteria Identifying Patients with Sepsis and Septic 
Shock25 
Additionally, according to the consensus, the clinical criteria for septic shock is defined 
as sepsis requiring vasopressor therapy to elevate MAP ≥ 65mmHg AND lactate >2 mmol/L(18 
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mg/dL) despite adequate fluid resuscitation. This was based on the finding that the risk-
adjusted hospital mortality was significantly higher in patients with fluid-resistant hypotension 
requiring vasopressors and hyperlactatemia (42.3% for serum lactate level of >2 mmol/L) 




In Opal’s study, randomization was performed by a computer-generated process. All 
principal investigators involved in the study were blinded to the results of the study.8 The 
intervention was kept blinded by keeping anakinra and placebo in identical packages prepared 
by the manufacturer.8   
Also, in another placebo-controlled, randomized, double-blind, parallel-group trial by 
Annane, D et al, randomization was performed through a concealed, computer-generated 
random number table. To blind the investigators of the assignment, pharmacists utilized 
sequentially numbered boxes containing the randomized treatment according to the generated 
list, which was confidentially delivered to the investigators.26  
In our study, all patients, family members, medical/pharmacy staff and related 
investigators will remain blinded throughout the study period utilizing similar randomization 
and blinding techniques as the two studies mentioned above.  
 
Primary Outcome Measures and End Points 
 
Opal’s study used 28-day mortality as well as the reanalysis by Shakoory.8,14 While 
some other studies have looked at overall mortality, studies such as Annane, D et al.26 studying 
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the effects of anakinra used the 28-day survival or mortality as their end point. Also, we based 
the mortality of our control group on the mortality rate reported by Stevenson et al.2 which used 
28-day mortality as well.2  
To decrease variability in length of stay and thus an overestimate or underestimate of 
mortality, we propose a 28-day mortality to observe a direct effect of anakinra therapy.  
 
Sample Size   
 
Opal and Fischer’s first phase III trial calculated the sample size needed to be 300 
patients per treatment group to detect a 35% reduction in 28-day all-cause mortality with 91% 
power at P=0.05. The calculation assumed the placebo mortality rate would be 40%.9 
The study was designed to enroll 1,300 patients but the study was terminated after an 
interim analysis at which point approximately half of the target population had completed the 
trial. Thus, their study power calculation was limited (power 1%).8  
The proposed study will aim to have an effect size similar to the original phase III trial 
by Fischer and Opal. However, given our study limitations of shorter time to conduct the study 
and smaller sample size, we will use a power of 80% with an alpha of 5% to calculate the 
sample size of this study. The assumed 28-day mortality for the intervention (anakinra) group is 
33.1% as reported by the confirmatory analysis by Opal.8 As for the control group, we 
determined the reported by Stevenson et al better reflected the target control group than Opal’s 
study.2 According to the study, the worldwide 28-day mortality rate of septic shock patients 
was reported to be 46.9% during years 1991-1995, which is the same time frame Opal’s 
confirmatory trial was conducted.2 Based on the data, we expect approximately 13% difference 
to be statistically significant. Although Shakoory’s reanalysis was underpowered, the 28-day 
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mortality in the intervention group was 34.6% compared to 64.7% in the placebo group, 
corresponding to a 47% reduction in mortality which further supports are estimation.14 
 We also propose our study to be a 1-sided test as the study is designed to test the hypothesis of 
reduction in mortality with intervention versus placebo, and we will not be testing the opposite 
hypothesis (increase in mortality rate with intervention). This is similar to the 1-sided test 
design conducted by Annane et al in determining the effect of corticosteroids in patients with 
septic shock.26 90% power with 0.05 type I error was used to calculate the sample size in this 
study.26 
 
Data Analysis  
 
Fischer and Opal’s first trial used a generalized Wilcoxon statistic to evaluate the 
survival times for the three groups studied. They also used Pearson's X2 analysis, one-way 
analysis of variance, or nonparametric rank comparisons using the Kruskal-Wallis Test to 
stratify the three groups according to demographic and pretreatment variables.9 
Opal and his colleagues used analysis of variance to test for treatment comparability of 
continuous baseline measurements in the second study. 28-day mortality rates and other 
categorical measurements were analyzed using Chi-square tests.8 
Both prospective trials followed the intent-to-treat principle to the primary end point.  
In the confirmatory study by Opal, an independent Safety and Efficacy Monitoring 
Board was tasked to perform an interim analysis approximately half of the target population 
had been enrolled and had completed the trial. The interim analysis was to evaluate major 
safety issues or statistically significant difference in outcome as well as to evaluate the 
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probability of study end points to be met.8 Our study will utilize a similar interim analysis by an 
independent review board at 1 year of study.  
 
 2.5 Conclusion  
 
 The meta-analysis by Friedman, Stevenson and Fleischmann highlighted the burden of 
sepsis and sepsis mortality remains high. As we make progress in understanding the complex 
physiology behind sepsis as well as the challenges in accurately staging and defining sepsis, 
there is a need to make equal progress in discovering effective, targeted therapies. Although 
Opal and his colleagues introduced interleukin-1 blockade in treatment of sepsis in his highly 
cited study over two decades ago, anakinra wasn’t recognized as potential therapy for patients 
with sepsis until the reanalysis of the original trial just recently by Shakoory et al.  
  As part of an effort to tackle the widespread challenge of sepsis, we propose a targeted 
double blind, randomized control trial evaluating the efficacy of anakinra verses placebo to 
reducing all-cause 28-day mortality in patients with septic shock, using the Sepsis-3 definition 









1. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. 
Critical care medicine. 1998;26(12):2078-2086. 
2. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of 
mortality trends among patients with severe sepsis: a comparative meta-analysis*. 
Critical care medicine. 2014;42(3):625-631. 
3. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and 
Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir 
Crit Care Med. 2016;193(3):259-272. 
4. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor 
and treatment of the septic shock syndrome. The Journal of infectious diseases. 
1991;163(6):1177-1184. 
5. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected 
treatment strategies for septic shock based on proposed mechanisms of pathogenesis. 
Ann Intern Med. 1994;120(9):771-783. 
6. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in 
monogenic autoinflammatory diseases and implications for common illnesses. J Allergy 
Clin Immunol. 2009;124(6):1141-1149; quiz 1150-1141. 
7. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying 
therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an 
international multicenter series. Arthritis and rheumatism. 2011;63(2):545-555. 
8. Opal SM, Fisher CJ, Jr., Dhainaut JF, et al. Confirmatory interleukin-1 receptor 
antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-
controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator 
Group. Critical care medicine. 1997;25(7):1115-1124. 
9. Fisher CJ, Jr., Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor 
antagonist in the treatment of patients with sepsis syndrome. Results from a 
randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome 
Study Group. Jama. 1994;271(23):1836-1843. 
10. Jain S, Thongprayoon C, Espinosa RE, et al. Effectiveness and Safety of Anakinra for 
Management of Refractory Pericarditis. Am J Cardiol. 2015;116(8):1277-1279. 
11. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated 
with anakinra. Nature clinical practice Rheumatology. 2008;4(11):615-620. 
12. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful 
treatment of severe paediatric rheumatic disease-associated macrophage activation 
syndrome with interleukin-1 inhibition following conventional immunosuppressive 
therapy: case series with 12 patients. Rheumatology (Oxford, England). 2011;50(2):417-
419. 
13. Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 
receptor antagonist, in the management of secondary hemophagocytic 
lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome 
in critically ill children*. Pediatr Crit Care Med. 2014;15(5):401-408. 
14. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is 
Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage 
42 
 
Activation Syndrome: Reanalysis of a Prior Phase III Trial. Critical care medicine. 
2016;44(2):275-281. 
15. Martinez ML, Ferrer R, Torrents E, et al. Impact of Source Control in Patients With 
Severe Sepsis and Septic Shock. Critical care medicine. 2017;45(1):11-19. 
16. Lagunes L, Encina B, Ramirez-Estrada S. Current understanding in source control 
management in septic shock patients: a review. Ann Transl Med. 2016;4(17):330. 
17. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 
2016;353:i1585. 
18. Taeb AM, Hooper MH, Marik PE. Sepsis: Current Definition, Pathophysiology, 
Diagnosis, and Management. Nutr Clin Pract. 2017;32(3):296-308. 
19. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in 
humans. Seminars in immunology. 2013;25(6):469-484. 
20. Zapata-Tarres M, Arredondo-Garcia JL, Rivera-Luna R, et al. Interleukin-1 receptor 
antagonist gene polymorphism increases susceptibility to septic shock in children with 
acute lymphoblastic leukemia. Pediatr Infect Dis J. 2013;32(2):136-139. 
21. Tolsma V, Schwebel C, Azoulay E, et al. Sepsis severe or septic shock: outcome 
according to immune status and immunodeficiency profile. Chest. 2014;146(5):1205-
1213. 
22. Trivedi V, Bavishi C, Jean R. Impact of obesity on sepsis mortality: A systematic 
review. Journal of critical care. 2015;30(3):518-524. 
23. Lundberg JS, Perl TM, Wiblin T, et al. Septic shock: an analysis of outcomes for 
patients with onset on hospital wards versus intensive care units. Critical care medicine. 
1998;26(6):1020-1024. 
24. Faine BA, Noack JM, Wong T, et al. Interhospital Transfer Delays Appropriate 
Treatment for Patients With Severe Sepsis and Septic Shock: A Retrospective Cohort 
Study. Critical care medicine. 2015;43(12):2589-2596. 
25. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus 
Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):801-810. 
26. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of 






CHAPTER 3 – STUDY METHODS 
3.1 Study Design 
 
This is a placebo-controlled, randomized, double-blind study to be performed at the 
adult medicine intensive care unit at Yale-New Haven Hospital(YNHH). 
Randomization will be obtained using a computer-generated random number sequence that will 
maintain concealed and blinded to all participants of the study including but not limited to 
study subjects, pharmacists, medical providers and research analysts. We plan to randomize 
patients into either the intervention(anakinra) group or the placebo group in 1:1 ratio.  
The primary objective of the study will be to evaluate the efficacy of anakinra in 
reduction of 28-day mortality in comparison with a placebo.  
 
3.2 Study Population and Sampling  
 
The study will screen all adult patients (≥18 years old) admitted to the YNHH Medical 
Intensive Care Unit during the study period to determine if the patient meets the criteria for 
septic shock according to the Sepsis-3 definition.1 The clinical criteria we will use to identify 
patients in septic shock an increase of two or more points of the SOFA score with vasopressor 
requirement to maintain a mean arterial pressure of 65mmHg or greater and serum lactate level 
greater than 2 mmol/L(>18 mg/dL) in the absence of hypovolemia.  
The evaluation of eligible participants will be conducted through the electronic medical 
record system, EPIC by a registered nurse research analyst hired by the investigators using 
flyers (Appendix F). The analyst will review patient’s medical records daily to identify patients 
that meet the eligibility criteria.  
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Exclusion criteria includes advanced directives, pregnancy, scheduled operations within 
28-days, and conditions that cause immunocompromise (i.e. HIV, hematologic malignancies).   
 
3.3 Recruitment Timeline   
 
We propose the following timeline for our study: 
 
Figure 5. Timeline of Planned Study 
This study will be conducted over a total of 2 years, including recruitment, data 
collection and analysis. Patients will be enrolled as identified for the first 22 months of study. 
All recruitment of subject will end by no later than 2 months prior to the completion of the 
study. Data will be collected throughout the study as patients are enrolled and the outcome 
















allowing two months for data analysis at each point. (See Appendix C for proposed study flow 
chart) 
 
3.4 Subject Protection and Confidentiality  
 
We plan to seek approval by the Human Investigation Committee (HIC) at Yale before 
August 2017 as specified above. Written informed consent will be obtained from eligible 
patients or their family members if patients are not able to provide consent (Appendix C). 
Special considerations for special patient populations, issues regarding breach of confidentiality 
and methods to ensure HIPAA compliance are all outlined in the consent form. To ensure 
safety of our participants, we plan an interim analysis at the 12-month mark. An independent 
safety monitoring board shall meet after at the interim analysis end point to decide whether the 
study shall continue or be terminated.  
All study investigators will be required to sign a Confidentiality and Non-Disclosure 
Agreement Form to ensure the confidentiality of data obtained throughout the study, in 
compliance with current HIPAA regulations (Appendix D). 
 
3.5 Study variables and measures 
  
The independent variable of this study will be the administration of anakinra. The 
intervention group will receive an initial 100mg bolus of anakinra at enrollment of trial 
followed by a 72-hr intravenous infusion at 2mg/kg/hr. The control group will receive normal 
saline as placebo in the same manner of administration (100mg bolus + 72-hr IV infusion of 
anakinra equivalent volume*). *anakinra is commonly manufactured in 100mg/0.67mL form.  
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 The primary dependent variable observed in this study will be 28-day, all-cause 
mortality. All eligible patients will be followed over the 28-day study period after study entry 
or until death, whichever occurs first. 
 Baseline data of the study participants will be collected at the time of enrollment by our 
research coordinator. The data set will include age, sex, race, BMI, comorbidities, pathogen of 
infection (if identified), SOFA score, lactate level, vital signs, and vasopressors administered. 
The research analyst will require access to EPIC, the Medical Intensive Care Unit of YNHH 
and workspace with computer access.  
  
3.6 Blinding of Intervention and Outcome  
 
The computer-generated list to randomize patients into the two arms of the study will be 
concealed to all participants and investigators of the study. The pharmacy will provide un-
labeled vials of either the placebo or anakinra following the sequence of the randomization list. 
A confidentiality form will be signed by all pharmacists and medical staff involved in the study 
to ensure blinding (Appendix C). Data analysis by the independent review board will be kept 
blinded to all study participants and investigators until termination of the study.  
 
3.7 Adherence  
 
There are no foreseen major concerns with adherence in our study population. However, 
a patient may withdraw from the study at any time for any reason as specified in the consent 
form. The data from patients that withdraw from the study will be censored at the time of 
withdrawal and included in the analysis.  
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To ensure adherence to intervention, the research analyst will confirm the 
administration of anakinra or placebo each day during the intervention period.  
 
3.8 Monitoring of adverse events  
 
Safety of Anakinra in human use is well documented in previous studies.2-7 We will 
continuously monitor for adverse reactions including but not limited to: headache, 
nausea/vomiting/diarrhea, opportunistic infection, arthralgia, fever, and cytopenia.  Given that 
anakinra is an immune suppressing agent and it is being administered to patients with severe 
bacterial infections, care to monitor for worsening infection or a high rate of new, hospital-
acquired infection will be taken. 
 
3.9 Sample Size Calculation  
 
To calculate our sample size, we used severe sepsis 28-day mortality of 46.9%8 reported 
by Stevenson et al. in their 2014 study of severe sepsis (including septic shock) worldwide. The 
expected 28-day mortality in the intervention group we used in our sample size study was 
33.1% as calculated in the reanalysis of the anakinra vs. placebo phase III trial.3,9 To detect a 
13.8% difference with 80% power and 0.05 alpha our predicted sample size needed was a total 






3.9 Analysis  
 
The primary outcome of the study (28-day, all-cause mortality rate) will be analyzed 
using Chi-square tests, which we determined to be the best method to analyze a binomial 
outcome. All analyses will be conducted on an intention-to-treat basis. Patient baseline 
characteristics and study variables will be stratified using multiple logistic regression to adjust 
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CHAPTER 4 – CONCLUSION 
 
The primary limitation of the proposed study may lie in its design as a single-center 
trial, which complicates the generalizability of the results. The advantage of a single-centered 
trial is that it helps lessen the variability that exists between individual clinician practice and 
sepsis treatment protocol on from institutional level. The more controlled setting of a single-
center, fixed care setting of the adult Medical Intensive Care Unit may provide a more uniform 
standard of care compared to a multi-centered study.  
Another possible limitation of the study is in its time restriction of a two-year 
timeframe, potentially making it difficult for the study to reach its target sample size based on 
the current incidence of septic shock. This may result in an underpowered study or the early 
termination of the study during the interim analysis if the target sample size is deemed not to be 
achievable.  
Determining the precise timing of anakinra administration for maximum efficacy has 
been a question that has been challenging to clinicians. The complexity of the inflammatory 
process makes it difficult to assess when the IL-1Ra blockade will be most beneficial to the 
patient. Finding the right balance between controlling a dysregulated host inflammation while 
allowing the body to respond appropriately to an infection remains a challenge and may work 
as an invisible confounding factor of outcome. However, we are reassured that by standardizing 
the timing of the intervention, we can reduce the confounding to a lesser degree. Although each 
patient may undergo a different physiological timeline of responding to sepsis and recovery 
time from septic shock may vary, the prospective design of the study allows for maximum 
correlation between cause and effect of the intervention planned.  
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The variability between entry criteria for sepsis has been a confounding factor in many 
previous studies due to the inconsistent definition of sepsis and septic shock. Following the 
recommendations set by the Sepsis-3 Consensus, we were able to standardize the entry criteria 
for septic shock thereby reducing the variability between patients in terms of baseline illness 
severity.  
Also, using a drug with an established safety profile minimizes the risk of adverse side 
effects, increasing the safety for our subjects. While unforeseen side effects are difficult to 
eliminate, we are hopeful there will be minimal risk of harm to our study population with the 
intervention planned.  
Despite novel efforts to treat sepsis and septic shock, mortality remains high and we are 
still in search of a definitive therapy. Positive results from this study can lead clinical practice 
in a new therapeutic approach to septic patients. Through immune modulation, our 
understanding the pathophysiology of sepsis in the past years may be translated into more 
effective therapy.  
While the mortality rate from sepsis has been slowly declining over the years, incidence 
is rising, possibly due to the aging population. Also, both the mortality rate and incidence 
remain much higher in lower income countries. Devising an easily reproducible, novel therapy 
may serve as a much-needed answer to the difficult question posed by septic shock, which 
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APPENDIX D – Consent Form for Study Participants 
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR. 1 (2016-2) 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
 
Study Title:  Reducing Mortality with Anakinra in Septic Shock 
 
Principal Investigator: Geoffrey Connors, MD 
Co-Principal Investigator: Juyeon Chung  
Funding Source: (To be determined) 
 
 
Invitation to Participate and Description of Project 
 
You are invited to participate in a research study designed to look at the efficacy of using anakinra, an 
interleukin-1 inhibitor in reducing mortality in patients with septic shock. You have been asked to participate because 
you meet the clinical criteria defined by the Sepsis-3 definition as “septic shock”. This study will aim to recruit 
approximately 400 participants admitted to the Medical Intensive Care Unit and Step-Down Unit of Yale-New 
Haven Hospital between August 2017 and June 2019. 
 
In order to decide whether or not you wish to be a part of this research study you should know enough 
about its risks and benefits to make an informed decision.  This consent form gives you detailed information about 
the research study, which a member of the research team will discuss with you.  This discussion should go over all 
aspects of this research: its purpose, the procedures that will be performed, any risks of the procedures, and possible 






Description of Procedures 
▪ As a participant of this study, you will be randomized to one of two groups:  
▪ The “placebo” group. This is the study “control” group. 
▪ The “anakinra” group. This is the study “intervention” group.  
▪ Randomization will be obtained by a computer-generated algorithm.  
▪ The clinicians, researchers and participants will all be blinded to the group assignments. This 
means all parties will not know which group a participant is assigned to.  
▪ The “placebo” group WILL NOT receive anakinra, an anti-inflammatory agent in addition to 
standard of treatment for septic shock. 
▪ The “anakinra” group WILL receive anakinra in addition to standard of treatment for septic shock. 
▪ For the anakinra group, 100 mg bolus of anakinra will be administered intravenously(IV) initially, 
followed by a 2mg/kg/hr IV infusion for 24hrs. For the placebo group, the same amount of normal 
saline will be administered. Normal saline is a non-harmful solution that is optimized to the 
concentration of your blood. The amount administered will be a negligible amount to have any 
significant physiological effects. It is also a part of standard of therapy for patients in septic shock.  
▪ The administration of anakinra or placebo should not require additional intravenous access than 
needed for standard treatment for septic shock.   
▪ The total length of participation in this study is 28 days.  
▪ Treatment related to this study will last 72 hours (3 days) from point of enrollment and initiation 
of treatment.  
▪ You will receive standard of care during the remainder of the hospitalization.  
▪ This study requires reviewing of participants’ medical record for demographic information as 
well as other information relevant to the study. For example, researchers of this study may collect 
information that may include but not limited to: your age, gender, race, height, weight, past 
medical history and medication history. This information will help researchers evaluate potential 
confounders in the results of this study. For research involving review of subject’s medical record, 
the consent form should explain what types of information will be collected, and why. 
 
You will be told of any significant new findings that are developed during the course of your 






Risks and Inconveniences 
▪ There are no significant foreseeable risks, discomforts or inconveniences associated with the 
study. 
▪ Anakinra has been proven to be safe for use in multiple clinical trials. 
▪ The most common reported side effect of anakinra is skin irritation at the injection site. Our study 
will utilize intravenous administration of anakinra, therefore eliminating the side effects of skin 
/tissue injection.  
▪ Other possible side effects of anakinra may include but not limited to: headaches, nausea, 
vomiting, diarrhea, joint pain, changes in blood cell count, or increased risk of infections. 
▪ There are no documented studies showing risk of using anakinra during pregnancy. However, as 
there are limited research on anakinra use in your population, please discuss with your clinician 
of if you are pregnant or could be pregnant.  
▪ Participation in this study may involve risks that are currently not known. 




▪ The goal of this study is to identify whether the use of anakinra can risk of death in septic shock 
patients. Thus, if you receive the assigned treatment, we hope it may improve your survival and 
outcome.  
▪ Any findings derived from this study will also serve to advance scientific knowledge for medical 




▪ There are no additional medical care costs you will be subject to in association with this research.  
▪ You will still be responsible for any co-pays required by your insurance company for standard 
treatment. 
▪ If you are assigned to receive the intervention(anakinra), it will be offered at no charge to you. 







▪ The use of anakinra is a new approach to sepsis care and therefore no parallel alternative 
treatment exists. There may be other experimental treatment to sepsis outside of this study. 
Please consult your physician if you are interested in knowing what other clinical trials may 
be available.  
▪ You may choose to not participate in this study.   
▪ Please note that alternatives are not limited to curative procedures.  For chronic or terminally 
ill subjects, alternatives may include procedures for symptom management, improving the 
ability to function, or palliative care.  
 
Confidentiality 
▪ Study subjects’ data will be kept for a maximum of 3 years before it is destroyed or de-identified. 
▪ Information about your study participation will be entered into your Electronic Medical Record 
(EMR). Once placed in your EMR, these results are accessible to all of your providers who 
participate in the EMR system. Information within your EMR may also be shared with others 
who are appropriate to have access to your EMR (e.g. health insurance company, disability 
provider.) 
▪ Authorized representatives of the Food and Drug Administration (FDA) [or a funding agency, 
such as the National Institutes of Health] and the manufacturer of anakinra may need to review 
records of individual subjects.  As a result, they may see your name; but they are bound by rules 
of confidentiality not to reveal your identity to others.  
▪ Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or State law.  
Examples of information that we are legally required to disclose include abuse of a child or elderly 
person, or certain reportable diseases.  [Describe the methods used to safeguard the confidentiality 
of subjects’ data (e.g., coding data or samples with numbers, storing research materials in locked 
cabinets, password-protecting data stored on a computer, etc.]  When the results of the research 
are published or discussed in conferences, no information will be included that would reveal your 
identity unless your specific consent for this activity is obtained.   
▪ Representatives from the Yale Human Research Protection Program, the Yale Human 
Investigation Committee (the committee that reviews, approves, and monitors research on human 
subjects) may inspect study records during internal auditing procedures.  However, these 
individuals are required to keep all information confidential.  
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In Case of Injury 
 
▪ If you are injured while on study, seek treatment and contact the study doctor as soon as you are 
able.   
▪ If you become ill or are physically injured due to the study [drug/device] [provide name of 
agent] or any investigational procedure specifically required by the plan for this study, you will 
not be responsible for the costs required to diagnose or treat such injury.  The costs of diagnosis 
and medical care for any complication, injury, or illness caused by the study [drug/device] or 
properly performed non-standard of care investigational procedure required by the study will be 
covered by the Sponsor as long as you have followed the directions of the study doctor. 
▪ If you receive a bill for any costs related to the diagnosis or treatment of your injury, please 
contact the study doctor. 
▪ You will not receive any other kind of payment.  There are no plans to pay you for such things 
as lost wages, disability, or discomfort as part of this study.  You do not give up any of your 
legal rights by signing this consent form. 
▪ Yale School of Medicine and Yale-New Haven Hospital do not provide funds for the treatment 
of research-related injury.  If you are injured as a result of your participation in this study, 
treatment will be provided.  You or your insurance carrier will be expected to pay the costs of 
this treatment.  No additional financial compensation for injury or lost wages is available. 
 
You do not give up any of your legal rights by signing this form. 
 
 
Voluntary Participation and Withdrawal 
Participating in this study is voluntary. You are free to choose not to take part in this study.   
Refusing to participate will involve no penalty or loss of benefits to which you are otherwise entitled 
(such as your health care outside the study, the payment for your health care, and your health care 
benefits).  However, you will not be able to enroll in this research study and will not receive study 





Withdrawing from the Study 
If you do become a subject, you are free to stop and withdraw from this study at any time during 
its course. This included during or after treatment with anakinra or placebo 
To withdraw from the study, you can call a member of the research team at any time and tell 
them that you no longer want to take part.  This will cancel any future appointments (if applicable).  
The researchers may withdraw you from participating in the research if necessary. Involuntary 
withdrawal may be due to development of serious side effects or early termination of the study.  
 Withdrawing from the study will involve no penalty or loss of benefits to which you are otherwise 
entitled.  It will not harm your relationship with your own doctors or with Yale-New Haven Hospital.  We 
would still treat you with standard therapy or, at your request, refer you to a clinic or doctor who can offer 
this treatment. 
When you withdraw from the study, no new health information identifying you will be gathered 
after that date.  Information that has already been gathered may still be used and given to others until the 
end of the research study, as necessary to insure the integrity of the study and/or study oversight.   
 
Questions 
We have used some technical terms in this form.  Please feel free to ask about anything you don't 
understand and to consider this research and the consent form carefully – as long as you feel is necessary 






I have read (or someone has read to me) this form and have decided to participate in the project described 
above.  Its general purposes, the particulars of my involvement and possible hazards and inconveniences 






      










Signature of Principal Investigator  Date 
  
                                      or 
 
_________________________________________________  ___________________ 
Signature of Person Obtaining Consent  Date 
 
If you have further questions about this project or if you have a research-related problem, you 
may contact the Principal Investigator: Juyeon Chung, (xxx) xxx-xxxx  
 
If, after you have signed this form you have any questions about your privacy rights, please 
contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with someone other 
than the researchers to discuss problems, concerns, and questions you may have concerning this 
research, or to discuss your rights as a research subject, you may contact the Yale Human 




APPENDIX E – Non-Disclosure and Confidentiality Agreement 
 
NON-DISCLOSURE AND CONFIDENTIALITY AGREEMENT 
Research Title: Reducing Septic Shock Mortality with Anakinra 
 
As a participant of this research I understand that I may have access to confidential 
information about the study intervention and participants. By signing this statement, I am 
demonstrating my understanding of my responsibilities to maintain confidentiality and agree to 
the following:  
 
▪ I understand that any identifying information about study sites and participants are 
completely confidential.  
 
▪ I agree not to divulge, publish, or otherwise make known to unauthorized persons or to 
the public any information obtained in the course of this research project that could 
identify the persons who participated in the study.  
 
▪ I understand that all information about study sites or participants obtained or accessed 
by me in the course of my work is confidential.  I agree not to divulge or otherwise make 
known to unauthorized persons any of this information, unless specifically authorized to 
do so by approved protocol or by the local principal investigator acting in response to 
applicable law or court order, or public health or clinical need. 
 
▪ I understand that I am not to read information about study sites or participants, or any 
other confidential documents, nor ask questions of study participants for my own 
personal information but only to the extent and for the purpose of performing my 
assigned duties on this research project. 
 
▪ I agree to notify the local principal investigator immediately should I become aware of an 
actual breach of confidentiality or a situation which could potentially result in a breach, 
whether this be on my part or on the part of another person. 
 
 
______________________________     ________________  _____________________ 
Signature           Date          Printed name 
 
______________________________     ________________   _____________________ 
Signature of local principal investigator     Date                     Printed name 
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APPENDIX F – Research Analyst Recruitment Flyer  
     
            
 
RESEARCH STUDY 
Would you like to participate in clinical research? 
We are looking for part-time or full-time research assistants to aid in the study of 
evaluating the efficacy of a new therapy for patients with septic shock.  
This is a paid position. Please contact the number below for information on compensation.  
 
Eligibility: Registered Nurse or equivalent level medical-degree.  
Responsibilities:  
-Dedicate 8-40hr/wk depending on full- or part-time participation 
-Review patient records on EPIC while complying to HIPAA(training is required) 
-Screen and interview potential study subjects in the Medical Intensive Care Unit at YNHH 
 
For questions or if you are interested in participating in this study, please contact the primary 
investigator:  
Juyeon Chung at (xxx)xxx-xxxx or email at juyeon.chung@yale.edu 
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*28-day, all-cause mortality 
**Sample size calculator was derived from http://clincalc.com/stats/samplesize.aspx. Rosner B. Fundamentals 
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